Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors

USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors Opinion Editorial USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors Finding the Right Tests for the Right Patients John T. Wilkins, MD, MS; Donald M. Lloyd-Jones, MD, ScM Cardiovascular disease (CVD) remains the leading cause of clusions are understandable from the policy perspective but death in the United States and a major source of morbidity. do not fully address the issues faced by individual patients Individuals in the United States havea1in3 chance of dying and clinicians in decisions about the relative merits of pri- from CVD anda2in3 chance mary preventive therapies. The main conclusion of the USPSTF—that more research of developing CVD before Related articles pages 272 and 2 death. However, control of needs to be performed to develop risk stratification algo- risk factors, such as with rithms that better identify individuals at risk who will benefit cholesterol-lowering statin medications, can substantially from primary prevention therapies (and those at sufficiently reduce the likelihood of mortality and morbidity among low risk, who will not benefit)—is correct. To date, there is no at-risk patients. Identifying individuals who will benefit high-quality evidence evaluating the morbidity, costs, CVD out- from this highly efficacious class of medications has been a comes, http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors

JAMA , Volume 320 (3) – Jul 17, 2018

Loading next page...
 
/lp/american-medical-association/uspstf-recommendations-for-assessment-of-cardiovascular-risk-with-co3TIEoi3r
Publisher
American Medical Association
Copyright
Copyright 2018 American Medical Association. All Rights Reserved.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2018.9346
pmid
29998347
Publisher site
See Article on Publisher Site

Abstract

Opinion Editorial USPSTF Recommendations for Assessment of Cardiovascular Risk With Nontraditional Risk Factors Finding the Right Tests for the Right Patients John T. Wilkins, MD, MS; Donald M. Lloyd-Jones, MD, ScM Cardiovascular disease (CVD) remains the leading cause of clusions are understandable from the policy perspective but death in the United States and a major source of morbidity. do not fully address the issues faced by individual patients Individuals in the United States havea1in3 chance of dying and clinicians in decisions about the relative merits of pri- from CVD anda2in3 chance mary preventive therapies. The main conclusion of the USPSTF—that more research of developing CVD before Related articles pages 272 and 2 death. However, control of needs to be performed to develop risk stratification algo- risk factors, such as with rithms that better identify individuals at risk who will benefit cholesterol-lowering statin medications, can substantially from primary prevention therapies (and those at sufficiently reduce the likelihood of mortality and morbidity among low risk, who will not benefit)—is correct. To date, there is no at-risk patients. Identifying individuals who will benefit high-quality evidence evaluating the morbidity, costs, CVD out- from this highly efficacious class of medications has been a comes,

Journal

JAMAAmerican Medical Association

Published: Jul 17, 2018

References